Abstract
Statement on Seasonal Trivalent Inactivated Influenza Vaccine (TIV) for 2010-2011: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI)†.
Highlights
I.1 Overview and Summary of ChangesThe purpose of this statement is to provide the National Advisory Committee on Immunization (NACI) recommendations for immunization with the seasonal trivalent inactivated influenza vaccine (TIV) for the 20102011 season, based on evidence available at this time.The seasonal trivalent vaccine for 2010-2011 incorporates the pandemic 2009 influenza A (H1N1) component, a new influenza A (H3N2) component and the same B component as last year.Immunization programs should focus on those persons at high risk of influenza-related complications, those capable of transmitting influenza to individuals at high risk of complications and those who provide essential community services
As circulation of pandemic H1N1 2009 (pH1N1) is anticipated in the coming season, there is support to consider offering vaccine (20102011 TIV containing the pH1N1 strain) to healthy persons who might not be included in the usual provincial program as well as continuing to target those considered to be at high risk of serious outcomes from pH1N1
For 2010-2011, NACI recommends that three additional groups that experienced a higher incidence of severe outcomes during both waves of the pH1N1 pandemic be considered as priority recipients for influenza vaccine
Summary
The purpose of this statement is to provide the NACI recommendations for immunization with the seasonal trivalent inactivated influenza vaccine (TIV) for the 20102011 season, based on evidence available at this time. For 2010-2011, NACI recommends that three additional groups that experienced a higher incidence of severe outcomes during both waves of the pH1N1 pandemic be considered as priority recipients for influenza vaccine. These new groups are persons with morbid obesity, Aboriginal peoples and children 2 to 4 years of age. NACI continues to recommend two doses of TIV for children under age 9 with no prior TIV, and one dose of TIV per season for children who have previously received one or more doses of TIV This recommendation applies whether or not the child received monovalent pH1N1 vaccine in 20092010
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
